ReviewFrontiers in pharmacology2026
Microcirculatory failure after successful recanalization in ischemic stroke: insights into mechanisms, imaging, and therapeutic strategies.
Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Early, effective reopening of an occluded large artery is a cornerstone of modern ischemic stroke care. Yet angiographic success does not consistently translate into tissue level reperfusion, nor does it reliably forecast good neurological recovery. Futile recanalization is multifactorial, and in many patients poor outcome may also reflect extensive irreversible injury already present at the time of recanalization because reopening is achieved too late to rescue substantial tissue. A growing body of work suggests that persistent microcirculatory dysfunction after recanalization may represent one important contributor to this discordance. In the post-recanalization setting, microvascular failure reflects intertwined ischemia-reperfusion processes: oxidative stress, inflammatory activation, endothelial injury, microthrombosis, and pericyte-driven capillary constriction, that together degrade capillary perfusion and exchange. As a result, tissue hypoxia can persist and the infarct core may continue to expand even when large-vessel patency has been restored. Experimental studies and emerging clinical observations, including trials of adjunct intra-arterial thrombolysis, increasingly support the idea that resolving residual microvascular obstruction can yield functional benefits beyond macrorecanalization alone. In parallel, progress in microcirculation imaging and monitoring, ranging from high-resolution optical tools in experimental models to angiography- and perfusion-derived metrics in patients, has strengthened
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.